Correlation between Serum Osteoprotegerin/Soluble Receptor Activator of Nuclear Factor-κβ Ligand Levels and the Left Ventricular Diastolic Dysfunction in Type 2 Diabetes

您当前的位置：

首页 >

文章列表页 >

Correlation between Serum Osteoprotegerin/Soluble Receptor Activator of Nuclear Factor-κβ Ligand Levels and the Left Ventricular Diastolic Dysfunction in Type 2 Diabetes

Clinical Research | 更新时间：2024-02-19

|

- Correlation between Serum Osteoprotegerin/Soluble Receptor Activator of Nuclear Factor-κβ Ligand Levels and the Left Ventricular Diastolic Dysfunction in Type 2 Diabetes
- Journal of Sun Yat-sen University(Medical Sciences) Vol. 44, Issue 6, Pages: 991-998(2023)
- 作者机构：
  
  中山大学附属第三医院特诊医疗中心，广东广州 510630
- 作者简介：
  
  WANG Yi-na； E-mail：377165615@qq.com
- 基金信息：
- DOI：10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0613
  CLC： R587.2
- Published：20 November 2023，
  
  Received：06 September 2023，
扫描看全文
郑奔容,唐喜香,江博雄等.2型糖尿病患者骨保护素和NF-κB受体活化因子配体与左室舒张功能障碍的相关研究[J].中山大学学报（医学科学版）,2023,44(06):991-998.

ZHENG Ben-rong,TANG Xi-xiang,JIANG Bo-xiong,et al.Correlation between Serum Osteoprotegerin/Soluble Receptor Activator of Nuclear Factor-κβ Ligand Levels and the Left Ventricular Diastolic Dysfunction in Type 2 Diabetes[J].Journal of Sun Yat-sen University(Medical Sciences),2023,44(06):991-998.
郑奔容,唐喜香,江博雄等.2型糖尿病患者骨保护素和NF-κB受体活化因子配体与左室舒张功能障碍的相关研究[J].中山大学学报（医学科学版）,2023,44(06):991-998. DOI： 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0613.

ZHENG Ben-rong,TANG Xi-xiang,JIANG Bo-xiong,et al.Correlation between Serum Osteoprotegerin/Soluble Receptor Activator of Nuclear Factor-κβ Ligand Levels and the Left Ventricular Diastolic Dysfunction in Type 2 Diabetes[J].Journal of Sun Yat-sen University(Medical Sciences),2023,44(06):991-998. DOI： 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0613.

摘要

目的

2

探讨2型糖尿病（T2DM）患者血清骨保护素（OPG）和可溶性NF-κB受体活化因子配体（sRANKL）水平与可能左室舒张功能障碍（LADD）的相关性。

方法

2

本研究纳入68例T2DM患者和37例健康对照者，利用ELISA方法测定血清OPG和sRANKL水平，同时利用心脏彩超测定T2DM患者左室舒张功能，E/A<1定义为 LADD。进一步将T2DM患者分为E/A≥1和E/A<1两个亚组。采用Spearman相关性分析、logistics回归分析和ROC曲线评估血清OPG和sRANKL与T2DM患者可能LADD的相关性。

结果

2

与健康对照者相比，T2DM患者血清OPG水平明显升高，差异有统计意义（

P

＜0.01），而sRANKL水平降低，但无统计学意义（

P

=0.032）。亚组分析则显示E/A

<

1组的OPG水平较E/A≥1组升高（

P

＜0.01），而sRANKL降低（

P

＜0.01）。Spearman相关性分析显示，血清OPG水平与E/A比值呈负相关，而sRANKL则与E/A比值呈正相关。单因素logistics回归分析显示，血清OPG水平［OR （95% CI）=1.068 （1.031，1.106），

P

<

0.001］和sRANKL水平［OR （95%

CI）=0.976 （0.959，0.992），

P

=0.003］与T2DM患者可能LVDD显著相关。ROC曲线分析显示，联合OPG与sRANKL诊断糖尿病患者可能LADD的敏感性为78.13%，特异性为88.3% （曲线下面积：0.857；95%CI=（0.768，0.946）；

P

＜0.001）。

结论

2

T2DM患者血清中升高的OPG和降低的sRANKL水平提示其可能与LADD相关。

Abstract

Objective

2

To study the possible correlation between serum osteoprotegerin （OPG）/soluble receptor activator of the nuclear factor κB ligand （sRANKL） levels and the left ventricular diastolic dysfunction （LADD） in patients with type 2 diabetes mellitus （T2DM）.

Methods

2

Totally 68 T2DM patients and 37 healthy controls were selected. Serum OPG and sRANKL were determined by solid-phase enzyme-linked immunosorbent assay （ELISA）. The left ventricular diastolic function of T2DM patients was measured by transthoracic echocardiography， where E/A < 1 were regarded as LVDD. T2DM patients were further divided into two subgroups according to E/A ratio （E/A≥1.0 and E/A<1）. Spearman correlation analysis， logistic regression and ROC curves were used to assess the possible correlation between serum OPG/sRANKL and LADD in T2DM patients.

Results

2

Compared with the healthy controls， serum OPG level in T2DM patients was higher with statistically significant difference （

P

<

0.01）， while serum sRANKL level was lower without statistically significant difference （

P

=0.32）. T2DM patients with E/A

<

1 had significantly higher OPG level and lower sRANKL level than those with E/A≥1

（P

<

0.01） in subgroup analysis. Spearman correlation analysis showed serum OPG level was negatively correlated with E/A ratio， while sRANKL was positively related with E/A ratio. In single factor logistic regression analyses， serum OPG ［OR （95% CI）=1.068 （1.031， 1.106），

P

<

0.001］ and sRANKL ［OR （95% CI）=0.976 （0.959， 0.992），

P

=0.003］ were significant correlation with LVDD in T2DM patients. ROC curve analysis showed that the sensitivity and specificity of combined OPG and sRANKL in diagnosing T2DM patients LADD were 78.13% and 88.3%， respectively （area under the curve： 0.857； 95% CI=（0.768， 0.946）；

P

<

0.001）.

Conclusions

2

The elevated OPG and decreased sRANKL levels may be associated with LADD in T2DM patients.

关键词

2型糖尿病左室舒张功能障碍骨保护素NF-κB受体活化因子配体

Keywords

type 2 diabetesleft ventricular diastolic dysfunctionosteoprotegerinreceptor activator of the nuclear factor κB ligand

references

Karwi QG， Ho KL， Pherwani S， et al. Concurrent diabetes and heart failure： interplay and novel therapeutic approaches［J］. Cardiovasc Res， 2022， 118（3）：686-715.

Ritchie RH， Abel ED. Basic mechanisms of diabetic heart disease［J］. Circ Res， 2020， 126（11）：1501-1525.

Kosmala W， Marwick TH. Asymptomatic left ventricular diastolic dysfunction： predicting progression to symptomatic heart failure［J］. JACC Cardiovasc Imaging， 2020， 13（1Pt 2）：215-227.

Kozakova M， Morizzo C， Fraser AG， et al. Impact of glycemic control on aortic stiffness， left ventricular mass and diastolic longitudinal function in type 2 diabetes mellitus［J］. Cardiovasc Diabetol， 2017，16（1）：78.

Dutka M， Bobiński R， Wojakowski W， et al. Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases［J］. Heart Fail Rev， 2022， 27（4）：1395-1411.

Forde H， Davenport C， Harper E， et al. The role of OPG/RANKL in the pathogenesis of diabetic cardiovascular disease［J］. Cardiovasc Endocrinol Metab， 2018， 7（2）：28-33.

Loncar G， Bozic B， Cvorovic V， et al. Relationship between RANKL and neuroendocrine activation in elderly males with heart failure［J］. Endocrine， 2010， 37（1）：148-56.

Bourron O， Phan F， Diallo MH， et al. Circulating receptor activator of nuclear factor kB ligand and triglycerides are associated with progression of lower limb arterial calcification in type 2 diabetes： a prospective， observational cohort study［J］. Cardiovasc Diabetol， 2020， 19（1）：140.

Maddaloni E， Coraggio L， Amendolara R， et al. Association of osteocalcin， osteoprotegerin， and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes［J］. Diabetes Metab Res Rev， 2023， 39（5）：e3632.

Moh AMC， Pek SLT， Liu J， et al. Plasma osteoprotegerin as a biomarker of poor glycaemic control that predicts progression of albuminuria in type 2 diabetes mellitus： A 3-year longitudinal cohort study［J］. Diabetes Res Clin Pract， 2020， 161：107992.

Vachliotis ID， Polyzos SA. Osteoprotegerin/receptor activator of nuclear factor-kappa B ligand/receptor activator of nuclear factor-kappa B axis in obesity， type 2 diabetes mellitus， and nonalcoholic fatty liver disease［J］. Curr Obes Rep， 2023， 12（2）：147-162.

Pezhman L， Sheikhzadeh Hesari F， Ghiasi R， et al. The impact of forced swimming on expression of RANKL and OPG in a type 2 diabetes mellitus rat model［J］. Arch Physiol Biochem， 2019， 125（3）：195-200.

Browner WS， Lui LY， Cummings SR. Associations of serum osteoprotegerin levels with diabetes， stroke， bone density， fractures， and mortality in elderly women［J］. J Clin Endocrinol Metab， 2001， 86（2）：631-637.

Yaturu S， Rains J， Jain SK. Relationship of elevated osteoprotegerin with insulin resistance， CRP， and TNF-alpha levels in men with type 2 diabetes［J］. Cytokine， 2008， 168-171.

Kiechl S， Wittmann J， Giaccari A， et al. Blockade of receptor activator of nuclear factor-κB （RANKL） signaling improves hepatic insulin resistance and prevents development of diabetes mellitus［J］. Nat Med， 2013， 19（3）：358-363.

向光大，孙慧伶，赵林双，等. 1型糖尿病患者胰岛素治疗前后血浆护骨素的变化［J］. 中华医学杂志， 2007， 87（18）： 1234-1237.

Xiang GD， Sun HL， Zhao LS， et al. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients［J］. Natl Med J Chin， 2007， 87（18）： 1234-1237.

Toffoli B， Pickering RJ， Tsorotes D， et al. Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop［J］. Atherosclerosis， 2011， 218（1）：61-68.

Eschler DC， Kulina G， Garcia-Ocana A， et al. Circulating levels of bone and inflammatory markers in gestational diabetes mellitus［J］. Biores Open Access， 2018， 7（1）：123-130.

O'Sullivan EP， Ashley DT， Davenport C， et al. Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes［J］. Diabetes Metab Res Rev， 2010， 26（6）：496-502.

Grigorescu ED， Lacatusu CM， Floria M， et al. Left ventricular diastolic dysfunction in type 2 diabetes-progress and perspectives［J］. Diagnostics （Basel）， 2019， 9（3）：121.

Zampetti S， Lucantoni F， Pacifico L， et al. Association of OPG-RANKL ratio with left ventricular hypertrophy and geometric remodeling in male overweight/obese youths［J］. J Endocrinol Invest， 2019， 42（4）：427-434.

Liu W， Feng W， Wang F， et al. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease［J］. Exp Mol Pathol， 2008， 84（3）：213-217.

Wang X， Liu J， Yang Y， et al. An update on the potential role of advanced glycation end products in glycolipid metabolism［J］. Life Sci， 2020， 245：117344.

Ndip A， Wilkinson FL， Jude EB， et al. RANKL-OPG and RAGE modulation in vascular calcification and diabetes： novel targets for therapy［J］. Diabetologia， 2014， 57（11）：2251-2260.

Galeone A， Grano M， Brunetti G. Tumor necrosis factor family members and myocardial ischemia-reperfusion injury： State of the art and therapeutic implications［J］. Int J Mol Sci， 2023， 24（5）：4606.

Marcadet L， Bouredji Z， Argaw A， et al. The roles of RANK/RANKL/OPG in cardiac， skeletal， and smooth muscles in health and disease［J］. Front Cell Dev Biol， 2022， 10：903657.

0

Views

8

下载量

0

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Related Articles

Development and Validation of a Predictive Risk Model for Vision-threatening Diabetic Retinopathy in Patients with Type 2 Diabetes

Clinical Effects of Chinese Medicine Fasting Therapy in Overweight/Obese Type 2 Diabetes Patients

Decreased Caveolin-1 Expression of Peripheral Blood Mononuclear Cells in Newly Diagnosed Type 2 Diabetic Patients and Its Relationship with Insulin Resistance

Association of Polymorphisms in CAV1/CAV2 Locus with Type 2 Diabetes in Chinese Han Population

Related Author

HUANG Sheng-song

LIU Jia-hui

CHEN Shu-hui

CHEN Min-yu

ZHANG Jian

LI Yu-ting

HUANG Wen-yong

LUO Jin

Related Institution

State Key Laboratory of Ophthalmology//Zhongshan Ophthalmic Center， Sun Yat-sen University//Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science

The Tenth Affiliated Hospital of Southern Medical University （Dongguan People's Hospital）

Department of Traditional Chinese Medicine， The Seventh Affiliated Hospital， Sun Yat-sen University

Postal code：510080
Tel：020-87331643，87330827 Email：xbmed@mail.sysu.edu.cn
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰